Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.

ABSTRACT:

Background

Patients on dual antiplatelet therapy following percutaneous coronary intervention often have indications for concurrent oral anticoagulation or triple antithrombotic therapy (TT). Although TT may decrease ischemic complications, it may confer increased bleeding risk.

Hypothesis

We hypothesize that the use of ticagrelor in TT is associated with higher risk of complications; accordingly, we sought to determine predictors of complications in patients on TT.

Methods

Patients discharged on TT after percutaneous coronary intervention were followed prospectively for 12 months. The primary endpoint was a composite of ischemic (death, myocardial infarction, stroke) and major bleeding complications or net adverse clinical event (NACE). A major secondary endpoint was

SUBMITTER: Fu A 

PROVIDER: S-EPMC6490865 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature